MODERN POSSIBILITIES FOR PROPHYLAXIS OF CATARACT PROGRESSION

Cataract is one of the  most  common  diseases, especially in the  elderly. Despite  the  fact that  the  share of elderly people  in economically developed countries is higher than  in developing countries, the incidence  of cataract in people over 50 years  in Western countries is 15% and it is about  40%  in developing countries. The reasons are  unbalanced nutrition,  lack of specialized ophthalmic  care  at the initial stages of the disease, the impact of adverse environmental conditions,  etc.  Surgical treatment is the only curative method. However, there are  not always enough indications for this treatment on the one hand, and it is not always possible due to patient’s unfavorable physical status, on the other  hand.  The supportive anti-cataract therapy  should be provided with the dynamic follow-up in such  cases. The pharmaceutical industry offers anti-cataract drugs  with a different composition  and properties, they are  based on the  mechanisms of the  onset  and development of the  disease. “Oxidative stress” is one  of the  main factors, which can  be the  cause of both  nuclear  and  cortical  cataracts. There  are scattering zones in the mature nucleus  of the lens, an increase in extracellular  spaces between corrugated membrane protein-like deposits in case of cataract. It is generally believed that  the  basis  of these deposits are  denatured, initially water-soluble  proteins, which turn  into opaque  substances due to the action of quinoids products formed through  the disturbed metabolism of aromatic aminoacids (tryptophan, tyrosine,  etc.).  Based  on this theory, an anti-cataract substance — pirenoxine was developed.  It inhibits the action of quinoids and prevents the formation of the len’s opacities  and the cataracts progression.

1. Ohrloff C. Epidemiology of senile cataract. In Hockwin 0., Sasaki K., Leske M.C. (eds). Risk Factors for Cataract Development. Karger: Basel, 1989; 1–5.

2. Hitesh Bhati, Manjusha R. Clinical study on evaluation of anti‑cataract effect of Triphaladi Ghana Vati and Elaneer Kuzhambu Anjana in Timira (immature cataract). Ayu, 2015;36(3):283–289. doi: 10.4103/0974‑8520.182762

3. Hitesh Bhati, Harisha C.R., Shukla V.J., Manjusha R. Pharmacognostical and phytochemical analysis of Triphaladi Ghana‑Vati — an Ayurveda polyhebral formulation for senile immature cataract. W. Jour. Of Pharmaceutical Res., 2017;6(4):1256‑1266. doi: 10.20959/wjpr20174‑8192

4. The World Health Report: Life in the 21st Century — A Vision for All. World Health Organization, Geneva, 1998;47.

5. Vonor K., Amedome K.M., Dzidzinyo K., Koutolbena K., Babla M., Balo K.P. Cataracts in rural areas in Togo: awareness and attitudes. Med. Sante Trop. 2016;26(3):259–261. doi:10.1684/mst.2016.0558

6. Minassian D.C., Mehra V. 3.8 million blinded by cataract each year. Br. J. Ophthalmol. 1990;74:341–343.

7. Yospaiboon Y., Yospaiboon K., Ratanapakorn T., Sinawat S., Sanguansak T., Bhoomibunchoo C.J. Management of cataract in the Thai population. Med Assoc Thai. 2012;95(7):S177–181.

8. Kupfer C. The conquest of cataract: A global challenge. Trans Ophthalmol Soc UK. 104:1‑10, In: Balasubramanian D, Bansal AK, Basti S, Bhatt KS, Murthy JS, Rao CM. The biology of cataract. The Hyderabad cataract research group. Indian J Ophthalmol. 1993;41:153–71.

9. Varma S.D. Scientific basis for medical therapy of cataracts by antioxidants. Am. J. Clin. Nutr. 1991;53(1 Suppl):335S‑345S.

10. Varma S.D., Hecde K.R., Kootan S. Inhibitor of senile induced cataract by caffeine. Acta Ophthalmol. 2010; 88(7):295–9.

11. Gao S., Qin T., Liu Z., Caceres M.A., Ronchi C.F., Chen C.Y., Yeum K.J., Taylor A., Blumberg J.B., Liu Y., Shang F. Lutein and zeaxanthin supplementation reduces H2O2‑induced oxidative damage in human lens epithelial cells. Mol Vis., 201;17(12):3180‑90.

12. West S.K., Valmadrid C.T. Epidemiology of risk factors for age‑related cataract. Ophthalmol., 1995;39(4):323–34.

13. Barker F.M..Dietary supplementation: effects on visual performance and occurrence of AMD and cataracts. Curr. Med. Res. Opin., 2010;26(8):2011–23.

14. Ma L., Hao Z., Liu R., Yu R., Shi Q., Pan J. A dose–response meta‑analysis of dietary lutein and zeaxanthin intake in relation to risk of age‑related cataract. Graefe's Arch. for Clin. Exp. Ophthalmology. 2014;252 (1): 63–70. doi: 10.1007/s00417‑013‑2492‑3.

15. Christen W.G., Manson J.E., Seddon J.M., Glynn R.J., Buring J.E., Rosner B., Hennekens C.H. A prospective study of cigarette smoking and risk of cataract in men. JAMA, 1992;268 (8):989–93.

16. Lipman R.M., Tripathi B.J., Tripathi R.C. Cataracts induced by microwave and ionizing radiation. Surv. Ophthalmol., 1988;33(3):267–72.

17. Reddy S.C. Electric cataract: a case report and review of the literature. European Journal of Ophthalmology, 1999;9(2):134–1388.

18. Christen W.G., Manson J.E., Seddon J.M., Glynn R.J., Buring J.E., Rosner B., Hennekens C.H. A prospective study of cigarette smoking and risk of cataract in men. JAMA, 1992;268 (8):989–93.

19. Wang S., Wang J.J., Wong T.Y. Alcohol and eye diseases. Surv. Ophthalmol. 2002;53 (5):512–25.

20. Weatherall M., Clay J., James K., Perrin K., Shirtcliffe P., Beasley R. Dose‑response relationship of inhaled corticosteroids and cataracts: a systematic review and meta‑analysis. Respirology, 2009;14(7):983–90.

21. Almony Arghavan, Holekamp Nancy M., Bai Fang, Shui Ying‑Bo., Beebe David. Small‑gauge vitrectomy does not protect against nuclear sclerotic cataract. Retina, 2012;32(3): 499–505. doi: 10.1097/IAE.0b013e31822529cf

22. Klein B.E., Klein R., Lee K.E., Grady L.M. Statin Use and Incident Nuclear Cataract. Journal of the American Medical Association, 2006;295(23):2752–8

23. Makarov I.A. [The possibilities of using the telemedicine within preoperative examinations of the lens‑nucleus density]. Vozmozhnosti telemeditsiny dlya predoperatsionnogo issledovaniya plotnosti yadra khrustalika. [Annals Ophthalmology]. Vestnik oftal'mologii. 2003;119 (4):56–59. (in Russ.)

24. Polunin G.S. [Medical treatment effectiveness of the cataracts]. [Consilium medicum. Ophthalmology]. Effektivnost' medikamentoznogo lecheniya katarakty. Consilium medicum. 2001;11(2): 9–11. (in Russ.)

25. Polunin G.S., Makarov I.A., Bubnova I.A. [Study of therapeutic efficiency of Catalin in patients with a senile cataract]. [Annals Ophthalmology]. Vestnik oftal'mologii. 2010;126(1):36–39. (in Russ.)

26. Abdelkader H., Alany R.G., Pierscionek B. Age‑related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens. J Pharm Pharmacol. 2015;67(4):537–50. doi: 10.1111/jphp.12355.

27. Williams D.L., Munday P. The effect of a topical antioxidant formulation including N‑acetyl carnosine on canine cataract: a preliminary study. Vet Ophthalmol. 2006;9(5): 311–6.

28. Stefek M., Karasu C. Eye lens in aging and diabetes: effect of quercetin. Rejuvenation Res. 2011;14(5):525–34.

29. Toh T., Morton J., Coxon J., Elder M.J. Medical treatment of cataract. Clin. Experiment. Ophthalmol. 2007;35 (7):664–71.

30. Wei L., Liang G., Cai C., Lv J. Association of vitamin C with the risk of age‑related cataract: a meta‑analysis». Acta ophthalmologica. 2016;94 (3):170–6. doi: 10.1111/aos.12688.

31. Javadi S., Yousefi R., Hosseinkhani S., Tamaddon A.M., Uversky V.N. Protective effects of carnosine on dehydroascorbate‑induced structural alteration and opacity of lens crystallins: important implications of carnosine pleiotropic functions to combat cataractogenesis. J Biomol Struct Dyn. 2016;19(8):1–19. doi: 10.1080/07391102.2016.1194230. Epub 2016 Aug 19.

32. Fukushi S., Tanaka N., Suzuki T. The effects of anti‑cataract drugs on free radicals formation in lenses. Nippon Ganka Gakkai Zaashi. 1991;95(11):1071‑76.

33. Hu C.L., Liao J.H., Hsu K.Y., Lin I.K., Tsai M.H. Role of prenoxine in the effects of catalin on in vitro ultraviolet induced lens protein forbodoty and senile induced cataractogenesis in vitro. Mol. Vis. 2011;17(12):1862‑70.

34. Balog Z., Sikic J., Voiukovic B., Rule S. Senile cataract and the adsorption activity of cytochrome C. Cell Antropol. 2001;25S:33‑36.

35. Kociecki J., Załecki K., Wasiewicz‑Rager J., Pecold K. Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract. Klin. Oczna. 2004;106(6):778‑82.

36. Babizhayev M.A. Potentiation of intraocular absorption and drug metabolism of N‑acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age‑related eye diseases. Drug Metabol Drug Interact. 2009;24(2‑4):275–323.

37. Kovalevskaya M.A., Vedrintseva N.V. [Oxidative stress as a predictor of cataract surgery outcomes]. Okislitel'nyy stress v prognozirovanii rezul'tatov fakoemul'sifikatsii katarakty [Ophthalmology in Russia]. Офтальмология. 2015;12(1):69–75. (in Russ.) DOI:10.18008/1816‑5095‑2015‑1‑69‑75